SANOFI-ADR (SNY) Stock News
NASDAQ:SNY - Nasdaq - US80105N1054 - ADR - Currency: USD
SNY Latest News, Press Relases and Analysis
Why SANOFI-ADR (NASDAQ:SNY) provides a good dividend, while having solid fundamentals.
Why the dividend investor may take a look at SANOFI-ADR (NASDAQ:SNY).
AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma
AstraZeneca's Breztri met primary goals in four asthma trials, including KALOS, LOGOS, LITHOS, and VATHOS, involving over 5,000 patients.
Mentions: AZN
Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides
On Tuesday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported first-quarter adjusted earnings per share of $8.22, down 14% year-over-year, missing the consensus of $8.82. The company reported sales of $3.03 billion, down 4%, missing the consensus of $3.29 billion. In the first quarter, U.S. net sales for Eylea HD and Eylea decreased 26% year-over-year to $1.04 billion, including $307 million from Eylea HD. Also Read: FDA Sets The Countdown: Regeneron’s Eylea HD Could Be Headed For Major Expan
Regeneron Pharmaceuticals Stock Sinks as Eylea Q1 Sales Trail Estimates
Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug—that missed analysts' estimates by a wide margin.
Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down
REGN reports lower-than-expected Q1 results. Lead drug Eylea sales plunge in the United States due to competition. Stock down.
Mentions: REGN
Why Viking Therapeutics Stock Popped Again Today
Cantor Fitzgerald thinks the GLP-1 diet drug VK2735 will be a "multi-blockbuster" for Viking stock.
AZN Q1 Earnings Beat, Stock Down on Soft Sales Performance of Key Drugs
AstraZeneca reports mixed first-quarter 2025 results. The fall in pre-market is likely due to the soft sales performance of key drugs across the oncology and rare disease segments.
JP Morgan Cautions Trade Tensions Are Weighing On Eastman Chemical Growth Prospects
JP Morgan analyst Jeffrey J. Zekauskas downgraded the rating for Eastman Chemical Company (NYSE:EMN) from Overweight to Neutral and cut the price forecast from $112.00 to $76.00. On April 25, the company reported first-quarter adjusted EPS of $1.91, beating the $1.89 estimate, while sales of $2.29 billion missed the $2.33 billion estimate. For the second quarter, Eastman anticipates adjusted EPS of $1.70-$1.90, below the consensus estimate of $2.18. The company expects a slight sequential volume
Private Equity Firms Target Defense Assets Once Seen as Toxic
(Bloomberg) -- Private equity firms are scouring for investment opportunities in European defense, chasing the once shunned sector in an effort to benefit from a historic switch to military expansion in the region.Most Read from BloombergNewsom Says California Is Now the World’s Fourth-Biggest EconomyAt Bryn Mawr, a Monumental Plaza Traces the Steps of Black HistoryNYC’s Congestion Toll Raised $159 Million in the First QuarterUS Cricket Deepens Bet on Texas With HQ Shift From CaliforniaLos Angel
Mentions: KKR
Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B
German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around $3.9 billion, expanding its portfolio of rare disease and cancer treatments.
Sobi and Sanofi's Foundation S extend partnership with the World Federation of Hemophilia Humanitarian Aid Program
/PRNewswire/ -- Sobi® (STO: SOBI) together with the World Federation of Hemophilia (WFH) and Sanofi, through its philanthropic organisation Foundation S,...
Sanofi and Sobi extend their partnership with the World Federation of Hemophilia Humanitarian Aid Program
/PRNewswire/ -- The World Federation of Hemophilia (WFH) and WFH USA, together with Sanofi, through its philanthropic organization Foundation S, and Sobi,...
French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit
Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), up 20.1% year over year and 18.7% in constant currency. The company reported first-quarter sales of 9.89 billion euros ($10.42 billion), beating the consensus of $9.77 billion. This was driven by launches, Dupixent, and favorable Beyfortus phasing. Sales increased 10.8% year over year and 9.7% on constant currency. U.S. sales were 4.66 billion and increased by 15.4%. The
Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed
Roche rode its pharmaceuticals growth to a sales beat, while Sanofi's report was more complicated.
Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More
BMY and REGN are in the spotlight this week following study data and regulatory updates, respectively.
Why Bank of America, JPMorgan Chase, and American Express Stocks All Popped Today
Here are three banks stocks benefiting from today's positive political news -- and two of them are worth buying.
Why AbbVie Inc. (ABBV) is Among the Best Stocks That Will Always Grow
We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best stocks that will always grow. The Looming Risk of a Recession in the US Threats of an impending recession are looming over the […]
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi
Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi are part of the Zacks top Analyst Blog.
UnitedHealth downgraded to Hold at Argus after guidance cut
As previously reported, Argus downgraded UnitedHealth (UNH) to Hold from Buy after the company cut its 2025 guidance, citing a jump in medical costs in its group Medicare Advantage business and weaker results from its Optum Health business. Medical cost pressures at Group Medicare Advantage will likely continue through the first half of 2025 and the cut in 2025 guidance makes it “more difficult to see a path to profitable growth in managed-care,” the analyst tells investors. Based on the updated
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.
Is Thermo Fisher Scientific Inc. (TMO) the Best American Dividend Stock to Buy According to Analysts?
We recently published a list of the 13 Best American Dividend Stocks to Buy According to Analysts. In this article, we are going to take a look at where Thermo Fisher Scientific Inc. (NYSE:TMO) stands against other best American dividend stocks. Dividend-paying stocks have long benefited investors by delivering consistent and solid returns. During periods of […]
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
Mentions: REGN
Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback
JNJ beats first-quarter estimates for earnings and sales. PFE ends the development of the weight loss pill danuglipron.
Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications
SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on lunsekimig and itepekimab studies.
Why Kingsoft Cloud Holdings Limited (KC) Surged On Friday?
We recently published a list of Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks. In this article, we are going to take a look at where Kingsoft Cloud Holdings Limited (NASDAQ:KC) stands against other Friday’s top performing stocks. The stock market finished the trading week on a positive note, wiping out earlier losses on Friday, […]
Why Certara Inc. (CERT) Surged On Friday?
We recently published a list of Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks. In this article, we are going to take a look at where Certara Inc. (NASDAQ:CERT) stands against other Friday’s top performing stocks. The stock market finished the trading week on a positive note, wiping out earlier losses on Friday, as […]
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.
All the Stocks Warren Buffett Bought in the Last 2 Recessions: Are They Smart Picks Now?
Tariffs Stoke Fears That Hung Debt Will Return
(Bloomberg) -- Deals in leveraged finance have stalled, and markets have been upended, raising the possibility that banks might once again get stuck with debt they’ve committed for acquisitions.Most Read from BloombergHousing Agency Aims to Relocate Its DC HeadquartersBoston Mayor Wu Embraces Trump Resistance as Campaign Heats UpThis Skinny Mexico City Tower Is Just 14 Feet Wide on One SideThe Irish Hot Press Is the Low-Tech Laundry Trick the World NeedsWhat Would ‘Transportation Abundance’ Look